HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation
Nasdaq Fintel reports that on September 6, 2023, HC Wainwright & Co. reiterated coverage of Acrivon Therapeutics (NASDAQ:ACRV) with a Buy recommendation.
Analyst Price Forecast Suggests 95.50% Upside
As of August 31, 2023, the average one-year price target for Acrivon Therapeutics is 23.46. The forecasts range from a low of 17.17 to a high of $27.30. The average price target represents an increase of 95.50% from its latest reported closing price of 12.00.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acrivon Therapeutics is 0MM. The projected annual non-GAAP EPS is -3.59.
What is the Fund Sentiment?
There are 113 funds or institutions reporting positions in Acrivon Therapeutics. This is an increase of 25 owner(s) or 28.41% in the last quarter. Average portfolio weight of all funds dedicated to ACRV is 0.09%, a decrease of 34.35%. Total shares owned by institutions decreased in the last three months by 2.48% to 15,204K shares.